MapLight Therapeutics, Inc. — Form 8-K
Filed July 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
MapLight announced positive topline results from the Phase 2 ZEPHYR trial (N=307) of ML-007C-MA in schizophrenia on July 27, 2026. The 210/3 mg BID dose met the primary endpoint with PANSS total score improvement of 4.5 points vs. placebo (effect size 0.37, p=0.015; effect size 0.50 in completers analysis, p=0.002). The drug also showed significant cognitive improvement (effect size 0.51, p=0.041) on a prespecified secondary endpoint in cognitively impaired patients, with favorable tolerability (no serious drug-related adverse events, 19.9% discontinuation rate, low GI discontinuations). The company plans to initiate a confirmatory Phase 3 pivotal trial (ZEPHYR-2) and engage with FDA at an End-of-Phase 2 meeting.
Why this rating
Phase 2 primary endpoint success in lead asset supports potential pathway to NDA, significant milestone for $419M-asset company. Cognitive signal is novel; confirmatory trial remains needed.
See more from July 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.